Boston, Massachusetts-based Tokai Pharmaceuticals is one of the clinical stage biopharmaceutical companies that focus its resources on the discovery and development of novelty products for cancer. Additionally, the business focuses on finding treatment for hormonally-driven diseases.
As of, the company has one product that is being developed for various treatments. Their product is branded as galeterone, which is an oral small molecule drug. This therapeutic has advantages over existing prostate cancer therapies and is intended as a treatment for patients with castration resistant prostate cancer (CRPC). This medication acts by disrupting the androgen receptor signalling pathway. The clinical trials of this therapeutic are conducted in the United States and in Canada. The business competes against Orion Corportion, Johnson & Johnson and Medivation, Inc., among other pharmaceutical companies.
Tokai Pharmaceuticals is one of the components of the Wilshire 5000 Index and publicly trades its common shares on the NASDAQ Global Market. The stocks of the company are marketed using the ticker symbol TKAI.
No comments:
Post a Comment